The incidence of primary<unk>  is approximately 3,000 cases per 100,000 individuals, mostly due to hypothalamic<unk> . The incidence of secondary<unk>  is approximately 3,300 per 100,000 individuals in Sweden. The prevalence of<unk>  is approximately 3,000 to 4,000 per 100,000 individuals worldwide. The prevalence of<unk>  was estimated to be 13,400 cases per 100,000 female athletes in Oslo marathon games. The case-fatality rate/mortality rate of<unk>  is less than 1%, and seen in patients of pituitary macroadenomas or generally brain lesions which cause<unk> . Primary<unk>  is usually first diagnosed among adolescents (around 16 years of age). There is no racial predilection for<unk> . Commonly, females in developed countries experience puberty and menarche earlier than females of developing countries. This can be attributed to nutritional and socioeconomic situation but since the age of diagnosis of primary<unk>  is based on the society's mean age of puberty onset and menarche, there is not any difference between developing and developed countries in terms of prevalence of<unk> .
Amenorrhea epidemiology and demographics
Dysmenorrhea epidemiology and demographics
Gonorrhea epidemiology and demographics
Bacterial vaginosis epidemiology and demographics
Cervicitis epidemiology and demographics
Trichomoniasis epidemiology and demographics
Chlamydia infection epidemiology and demographics
Trichinosis epidemiology and demographics